Objective: The myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant hematopoietic stem cell disorders, characterized by cytopenias (anemia, neutropenia and thrombocytopenia) accompanied by abnormal cellular maturation; a variable risk of transformation to acute leukemia.